Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Chemotherapy. The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States

Survival: 17.9 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Houston, TX
Hospital: The University of Texas M. D. Anderson Cancer Center
Journal: Link
Date: 9/2008

Patients: This phase II study involved 83 patients with metastatic renal cell carcinoma (kidney cancer). There were 65 men and 18 women in the study. These patients had received previous treatment with immunotherapy, and then their disease progressed. Most had previously been treated with interferon-alfa or interleukin-2.

Treatment: Patients were treated with the chemotherapy drugs gemcitabine and capecitabine.

Toxicity: Grade 4 toxicities occurred in 22% of patients, the most common being neutropenia followed by leucopenia and thrombocytopenia. Grade 3 toxicities, including neutropenia, leucopenia, thrombocytopenia, diarhhea, vomiting, mucositis, and fatigue occurred in 75% of patients. Grade 2 toxicities were the most common, occurring in 93% of patients.

Results: The median overall survival was 17.9 months.

Support: This study was supported by Roche and Eli Lilly. Eli Lilly markets gemcitabine as Gemzar, and Roche markets capecitabine as Xeloda.

Correspondence: Dr. Nizar M. Tannir

E-mail to a Friend Email Physician More Information